Enzo Life Sciences launches SMN protein assay system
The SMN ELISA kit will enable and expedite drug discovery, development and therapy for Spinal Muscular Atrophy, a genetic cause of mortality in infants and toddlers. The SMN
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.
The study result suggested that INC42 has reduced spleen size in patients with primary myelofibrosis (MF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF), when compared with